Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

The evolving nmCRPC treatment landscape - what is the role of bicalutamide?

Nubeqa Header Image

Description

Professor Philip Cornford, an expert in the field of nmCRPC and the EAU prostate cancer guidelines chair, speaks on the updated European Association of Urology (EAU) guidelines and shares his insights on the use of bicalutamide in the evolving non-metastatic castration-resistant prostate cancer (nmCRPC) treatment landscape.


Within this bitesize video, Professor Cornford explores:

  • His role as urologist in the management of nmCRPC patients
  • How nmCRPC patients were treated and monitored historically
  • The current and evolving nmCRPC treatment landscape
  • The potential benefits of treatment with second generation ARis 
  • The impact of second generation ARi licencing on the use of bicalutamide in nmCRPC management

This video is organised and funded by Bayer plc.

NUBEQA▼ GB Prescribing Information
NUBEQA▼ NI Prescribing Information

Speakers
    • Phillip CornfordProfessor Philip Cornford

    Professor Philip Cornford trained in London and Liverpool and was appointed as Consultant Urological Surgeon in 2001 at Royal Liverpool and Broadgreen University Hospital NHS Trust. He is also Honorary Associate Professor at the University of Liverpool, UK. Professor Cornford’s clinical practice has focussed on urological malignancies while also actively contributing to research and recruiting to a number of clinical trials. He is Chair of the European Association of Urology (EAU) Prostate Cancer Guidelines Panel and a member of the EAU Guidelines Office Board.

BAUS 2023: The role of Urologists in the MDT
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1319, February 2024
BAUS 2022: Navigating treatment decisions in nmCRPC patients
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1298, February 2024
ASCO-GU 2023: The DEAR study in nmCRPC
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1296, February 2024

PP-NUB-GB-1320 | February 2024